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A novel allosteric modulator of the cannabinoid CB1 receptor
ameliorates hyperdopaminergia endophenotypes in rodent
models
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Jibran Y. Khokhar3, Ali Salahpour1, Amy J. Ramsey 1, Michelle Glass2, Iain R. Greig5 and Ruth A. Ross1
The endocannabinoid system (eCBs) encompasses the endocannabinoids, their synthetic and degradative enzymes, and
cannabinoid (CB) receptors. The eCBs mediates inhibition of neurotransmitter release and acts as a major homeostatic system.
Many aspects of the eCBs are altered in a number of psychiatric disorders including schizophrenia, which is characterized by
dysregulation of dopaminergic signaling. The GluN1-Knockdown (GluN1KD) and Dopamine Transporter Knockout (DATKO) mice are
models of hyperdopaminergia, which display abnormal psychosis-related behaviors, including hyperlocomotion and changes in
pre-pulse inhibition (PPI). Here, we investigate the ability of a novel CB1 receptor (CB1R) allosteric modulator, ABM300, to ameliorate
these dysregulated behaviors. ABM300 was characterized in vitro (receptor binding, β-arrestin2 recruitment, ERK1/2
phosphorylation, cAMP inhibition) and in vivo (anxiety-like behaviors, cannabimimetic effects, novel environment exploratory
behavior, pre-pulse inhibition, conditioned avoidance response) to assess the effects of the compound in dysregulated behaviors
within the transgenic models. In vitro, ABM300 increased CB1R agonist binding but acted as an inhibitor of CB1R agonist induced
signaling, including β-arrestin2 translocation, ERK phosphorylation and cAMP inhibition. In vivo, ABM300 did not elicit anxiogenic-
like or cannabimimetic effects, but it decreased novelty-induced hyperactivity, exaggerated stereotypy, and vertical exploration in
both transgenic models of hyperdopaminergia, as well as normalizing PPI in DATKO mice. The data demonstrate for the first time
that a CB1R allosteric modulator ameliorates the behavioral deficits in two models of increased dopamine, warranting further
investigation as a potential therapeutic target in psychiatry.
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INTRODUCTION
Dysregulation of dopaminergic and glutamatergic signaling are
thought to underpin the development of psychosis and schizo-
phrenia [1]. Pharmacological treatment of schizophrenia and
psychosis includes the use of antipsychotics, which act as
orthosteric receptor antagonists/partial agonists of various GPCR
targets, including dopamine receptor D2 and serotonin receptor
5HT1A. However, antipsychotics are associated with extrapyramidal
side effects, sedation, metabolic syndrome, and weight gain [2, 3].
The endocannabinoids, anandamide (AEA) and 2-
arachidonoylglycerol (2-AG), are orthosteric agonists of the canna-
binoid CB1 receptor (CB1R). CB1R are expressed presynaptically on
various neuronal types, including GABAergic, glutamatergic and
serotonergic neurons, where they mediate an inhibition of
transmitter release. While not directly expressed on dopaminergic
neurons, the endocannabinoid system acts as a crucial filter that
integrates both inhibitory and excitatory signaling that modulates
dopamine neuron signaling [4]. Furthermore, studies have shown
that the endocannabinoid system is a negative modulator of both
D1 and D2 receptor-mediated behaviors, implicating them in basal
ganglia disorders [5]. As such, in combination with the complex
dysregulation and circuit-based mechanisms for brain region-
dependent alterations in dopaminergic signaling in psychiatry, this
suggests that the CB1R may be a more attractive, alternative
therapeutic target to the classical D2 receptor antagonism
approaches of antipsychotics [4].
Furthermore, there is strong evidence from humans that both
endocannabinoid levels and CB1R are dysregulated in schizo-
phrenia [6–9]. Serum and CSF levels of AEA are higher in patients
with schizophrenia at all stages of the illness and are normalized
after treatment with antipsychotics. CB1R expression and binding
is higher in post-mortem brain tissues of patients with schizo-
phrenia [6, 9]. While the endocannabinoid system seems to be an
important potential therapeutic target in psychiatry, targeting
CB1R at the orthosteric site has not yielded beneficial clinical
outcomes. The CB1R orthosteric inverse agonist, rimonabant, was
effective treating obesity and metabolic syndrome, but caused
suicidal ideation and was withdrawn from the market [10–12].
Here, we propose to investigate a novel pharmacological
approach of targeting the CB1R.
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In 2005, we discovered the CB1R allosteric site and the original,
prototype allosteric modulator, Org27569. This compound has
served as a tool compound to characterize the allosteric site but is
not a drug candidate. Org275, and related compounds, display an
atypical, complex allosteric profile at CB1R [13, 14]. Org275 increases
the Bmax of [
3H] CB1R agonist binding but functionally acts as an
inhibitor of CB1R agonist-mediated signaling [13, 15]. Importantly, in
October 2019, Shao et al. [16] elucidated the ternary crystal structure
of CB1R in complex with agonist and Org275. The structure shows
that Org275 binds to a cholesterol-binding site on the CB1R,
suggesting that the compound works by partitioning into the
bilayer and competing with endogenous cholesterol for this surface.
Previous studies have demonstrated that cholesterol may act as an
endogenous modulator of CB1R [17]. There is growing evidence that,
instead of targeting the orthosteric site of CB1R, the allosteric site
may have key advantages [15, 18, 19]. By modulating the effects of
the endogenous ligand, normal physiological tone (spatial and
temporal effects of ligand binding to the receptor) are maintained,
as opposed to the non-physiological binding and distribution seen
with exogenous direct ligands such as orthosteric agonists or
antagonists.
Since discovering the CB1R allosteric site in 2005, and identifica-
tion of Org275 as the first CB1R-negative allosteric modulator [13],
we, and others, have worked to develop both CB1R-negative and
-positive allosteric modulators. The positive allosteric modulators
developed by us, and others, have shown efficacy in the treatment
of neuropathic pain [20] and other therapeutic indications [21]. As
Org275, and related compounds, have insufficient metabolic
stability, in order to further investigate the potential of this unique
class of CB1R allosteric modulator, we embarked on a chemistry
campaign, with the goal of generating new molecules with
improved drug-like characteristics that are more suitable for
in vivo testing and clinical development. Our working hypothesis
is that the unique pharmacological profile of CB1R allosterics
provides a distinctive pharmacological approach for modulation of
the endocannabinoid system in complex disorders, and offers an
alternative to CB1R orthosteric antagonists [22]. The in vivo
outcomes of this complex mechanism are yet to be elucidated,
particularly in models in which the endocannabinoid system is
dysregulated.
Here, we present data on the effects of a novel CB1R allosteric
modulator, ABM300, in two distinct transgenic mouse models,
both of which present with a state of hyperdopaminergia. Both
the GluN1-Knockdown (GluN1KD) and Dopamine Transporter
Knockout (DATKO) mice have increased synaptic dopamine in
subcortical regions [23–25], which is implicated in their pheno-




Animal housing and experimentation were carried out in
accordance with the Canadian Council in Animal Care (CCAC)
guidelines for the care and use of animals and following protocols
approved by the Faculty of Medicine and Pharmacy Animal Care
Committee at the University of Toronto and the University of
Guelph Animal Care Committee, respectively.
Compound synthesis
See Supplementary Information for details.
Pharmacokinetic analyses
Microsomal stability assays were conducted by Cyprotex Ltd
(Macclesfield, UK). The in vitro metabolic stability of ABM300 was
measured in the presence of human or rat liver microsomes by
determination of the rate of compound disappearance. Single
dose in vivo PK studies were conducted by Sai Life Ltd
(Pune, India) to investigate the plasma pharmacokinetics and
brain distribution of ABM300 in male C57Bl/6 mice following a
single intraperitoneal (i.p.) administration of a 10mg/kg dose.
Predictive model of ABM300 bound to CB1R
The crystal structure of the CB1R-CP55940-Org275 complex (PDB
code 6kqi) [16] was loaded into ICM (Molsoft, San Diego, CA),
hydrogens were added, and rotameric states of hydroxy groups,
histidine, asparagine, and glutamine side-chains optimized. ICM’s
ligand editor was used to strip Org275 to the indole core scaffold
shared with ABM300, and to incrementally grow the scaffold into
ABM300, with a Monte Carlo-based energy minimization in the
internal coordinate space at each step [32].
Equilibrium-binding assays
Binding assays in hCB1R CHO cells were performed by Eurofins
Cerep with the CB1R agonist, [
3H]CP55,940 (0.5 nM, Kd of 3.5 nM).
Non-specific binding was defined in the presence of 10 µM
WIN55,212-2.
PathHunter® β-arrestin assay
The PathHunter® β-Arrestin assay was conducted by Eurofins
Pharma Discovery Services (further details can be found at https://
www.eurofinsdiscoveryservices.com).
ERK1/2 phosphorylation assay
CB1R-mediated ERK1/2 phosphorylation was quantified using an
AlphaLISA® Surefire® Ultra™ pERK1/2 Assay (PerkinElmer, Wood-
bridge, ON) according to the manufacturer’s protocol, in hCB1R
CHO cells plated at a density of 40,000 cells/well (96-well). ABM300
IC50 values were determined in the presence of increasing
concentrations of ABM300 at the EC80 for CP55,940 (40 nM).
Results are presented as the percent stimulation of ERK1/2
phosphorylation by CP55,940 alone.
Cyclic AMP (cAMP) assays
A DiscoverX HitHunter® cAMP Assay for Small Molecules
(DiscoverX, Fremont, CA) was used to quantify cAMP levels as
per the manufacturer’s instructions. hCB1R CHO cells were seeded
at a density of 40,000 cells/well (white 96-well), and after 24 h
were serum-starved in the presence of 0.1% Bovine Serum
Albumin for 60 min prior to pretreatment for 30 min with
increasing concentrations of ABM300 (10−10–10−5 M) and a final
30min incubation with 40 nM CP55,940 and 5 μM forskolin.
The cAMP BRET experiments were performed as previously
described [33, 34]. Briefly, hCB1R HEK293 cells were transfected
with 5 µg/10 cm dish of the CAMYEL biosensor using polyethyle-
nimine. After 24 h, the cells were plated into white 96-well plates
(PerkinElmer) at a density of 60,000 cells/well.
Drug administration
The following drugs were administered in a volume of 10 mL/kg
via i.p. injections in a vehicle consisting of 95% ethanol, Tween80,
and 0.9% NaCl in a 1:1:18 ratio, 30 min before behavioral testing,
unless otherwise stated: ABM300 (10 mg/kg), rimonabant (RIM;
10mg/kg, Cayman Chemical, Cat.# 9000484, Ann Arbor, MI),
olanzapine (OLA; 1 mg/kg, Millipore Sigma, Cat.# O1141, Toronto,
ON, CA), and Δ9-tetrahydrocannabinol (THC; 10 mg/kg, gift from
MedReleaf, Markham, ON, CA).
Cannabinoid-induced tetrad behaviors
Male C57Bl/6J mice (PD > 70) were tested on the cannabinoid-
induced tetrad, as previously described [35].
Behavioral testing in murine models of hyperdopaminergia
The effect of ABM300 was compared to OLA. GluN1KD (F1 on
C57Bl/6J x 129/SvlmJ background) [26] and DATKO (C57Bl/6J
background) [24] mice were used as murine models of
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hyperdopaminergia. All mice were tested as follows: Day 1—open-
field test and Day 3—pre-pulse inhibition, as previously described
[28, 30, 36, 37].
Quantification and statistical analysis
For in vitro assays, results were analyzed by non-linear regression
analysis of sigmoidal dose-response curves. For in vivo assays,
statistical parameters, the definition of measures and statistical
significance are reported in the figures and the figure legends. Data
are represented as mean ± SEM. Studies and data analysis were not
blinded. Differences in means were considered statistically signifi-
cant at p < 0.05. All data analyses were performed using GraphPad





zol-2-amine) showed promising in vitro metabolic stability in
human and rat liver microsomal preparations with half-life values
of 109 and 110min (compared to a typical developmental target
for progression of > 45 to 60 min), respectively (CLint= 12.7 ± 3.4
and 12.6 ± 2.0 µL/min/mg protein). Subsequent in vivo pharma-
cokinetic studies in male C57Bl/6 mice (8 timepoints, N= 3
per timepoint) confirmed acceptable metabolic stability for our
studies (T1/2 ~2 h) and CNS exposure, with a brain to plasma ratio
of 0.77 from a dose of 10 mg/kg, i.p., (AUC8h brain/AUC8h plasma)
and brain concentrations of 374 ± 39 ng/mL at 30 min (Supple-
mentary Fig. S1 and Supplementary Table S1).
Docking model of ABM300 bound to CB1R
A model of ABM300 bound to CB1R was derived from the CB1-
CP55940-Org275 ternary complex [16] (Fig. 1). ABM300 recapitulates
hydrophobic interactions observed with Org275 in the crystal
structure. Owing to its increased rigidity, ABM300 needs to shift by 2
Å towards the wall formed by I141 to accommodate the phenyl ring
that abuts I245. The docked conformation optimally occupies the
pocket, the oxadiazole ring is stacked against the indole of W241,
and the secondary amine bridging the phenyl and oxadiazole rings
is engaged in a hydrogen-bond with C238.
In vitro pharmacology: ABM300 increases agonist binding but
inhibits CB1R orthosteric agonist signaling
In line with our previous studies using a related compound
(Org275) [13], we find that ABM300 causes a significant and
concentration-dependent increase in the specific binding of [3H]
CP55,940 to hCB1R CHO (Fig. 2a) with an Emax value of 328 ± 47%
and a EC50 value of 132 nM (pEC50 6.90 ± 0.09) and an α value of
4.33 ± 0.79 (logα 0.622 ± 0.08) (Supplementary Table S2).
In the PathHunter® β-arrestin CB1R assay, CP55,940-stimulated
β-arrestin recruitment with an EC50 value of 5.37 nM (pIC50 8.28 ±
0.06) and an Emax of 104.3 ± 0.90%. In the presence of the EC80 of
CP55,940 (10 nM), ABM300 produced a concentration-related
reduction in β-arrestin recruitment with an IC50 value of 49.7 nM
(pIC50 7.31 ± 0.02) (Fig. 2b).
Using an AlphaScreen® SureFire® ERK1/2 phosphorylation assay
kit, we measured the effect of ABM300 on activation of ERK1/2
phosphorylation by CP55,940 in hCB1R CHO cells. In the presence
of vehicle, CP55,940 induced ERK1/2 phosphorylation with an EC50
of 12.1 nM (pEC50 8.14 ± 0.23) (Fig. 2c). At concentrations of 100 or
1000 nM, ABM300 significantly decreased CP55,940 Emax (efficacy),
to 40.3 ± 5.57% and 14.7 ± 5.22%, respectively (Fig. 2c). ABM300
alone did not affect ERK1/2 phosphorylation at concentrations up
to 10 µM (Fig. 2c). Additionally, 100 or 1000 nM ABM300 signifi-
cantly decreased the Emax (efficacy) of AEA from 100.3 ± 0.20% to
80.23 ± 14.4% and 31.88 ± 6.09%, respectively (Fig. 2d). In the
presence of the EC80 (40 nM) of CP55,940, ABM300 produced a
concentration-related reduction in ERK1/2 phosphorylation with
an IC50 value of 47.0 nM (pIC50 7.38 ± 0.12) (Fig. 2e). CP55,940
inhibited forskolin-stimulated cAMP accumulation in hCB1R CHO
cells (data not shown). At CP55,940 EC80 (40 nM), ABM300 blocked
this inhibition with an IC50 value of 379 nM (pIC50 6.45 ± 0.08)
(Fig. 2f).
We further characterized the real-time kinetic effect of ABM300
using a cAMP BRET sensor assay in HEK293 cells. Similar to
Fig. 1 Molecular structure and docking model of ABM300 bound to CB1R. a Overall structure of CB1R (PDB code: 6kqi) with bound Org275
(orange). The pregnenolone allosteric-binding site is highlighted in cyan [60], b Molecular structures of ABM300 and Org275. c Overall model
showing ABM300 and surrounding side-chains. d Space filling representation showing that ABM300 occupies optimally the negative allosteric
modulator-binding pocket. e ABM300 superimposed with the crystal structure of Org275 (orange) bound to CB1R (PDB code: 6kqi). The
molecular surface of CB1R is color-coded based on binding properties. Green: hydrophobic. Red: hydrogen-bond acceptor. Blue: hydrogen-
bond donor.
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previous observations with Org275 [38], ABM300 produced a
complex, concentration and time-dependent modulation of
agonist-mediated regulation of cAMP levels (Fig. 2g, h). Levels of
cAMP were measured over time with a high concentration of
CP55,940 (1 μM) in the presence of varying concentrations of
ABM300. Consistent with Org275 observations, ABM300 did not
affect the initial inhibition of cAMP by CP55,940 but, following a
concentration-dependent “lag” in drug onset, inhibition of the
agonist effect became apparent. At high concentrations, the
ABM300 inhibitory effect overcame the CP55,940 effect and
further enhanced cAMP levels above those produced by forskolin
alone—reflecting inverse agonism.
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ABM300 does not bind to the CB2R and does not have off-target
effects in a Safety Screen® 44 panel
Off-target effects of ABM300 were assessed using the SafetySc-
reen44, conducted at Eurofins Discovery Services. The screen
assesses the selectivity of the compound on a diverse panel of
targets that includes GPCRs, drug transporters, ion channels, nuclear
receptors, kinases, and other non-kinase enzymes. The screen
employs radioligand binding or enzyme assays for these 44 targets.
At 1 µM, ABM300 did not display any significant binding to these
targets, including; receptors CB2, Dopamine D1 and D2, NMDA,
5HT1A, 5HT1B, 5HT2A, 5HT2B, and 5HT3 (Supplementary Fig. S2).
ABM300 has no effect in the cannabinoid-induced tetrad alone
and does not display anxiogenic-like effects
We confirmed that ABM300 (10mg/kg) did not have agonist
activity via the cannabinoid-induced tetrad, compared to THC (10
mg/kg). In all four tetrad measures (Fig. 3), THC, but not ABM300,
produced effects (p < 0.0001 for all outputs). Previous reports
demonstrated adverse effects observed with CB1R orthosteric
agonists/inverse agonists [39, 40]. Possible anxiogenic effects of
ABM300 (10 mg/kg) were investigated using the EPM and
compared to rimonabant (10mg/kg) (Supplementary Fig. S3).
ABM300 did not affect time spent in the open arms (p= 0.3335),
Fig. 2 ABM300 increases agonist binding but inhibits CB1R orthosteric agonist signaling through arrestin recruitment, ERK
phosphorylation and cAMP signaling. a ABM300 increases [3H]CP55,940 binding to hCB1R CHO cell membranes. b ABM300
concentration-dependently decreases CP55,940 (10 nM)-mediated arrestin recruitment, with the PathHunter® β-arrestin assay. c ABM300
concentration-dependently decreases ERK phosphorylation at the EC80 concentration of CP55,940 (40 nM), using the AlphaScreen® SureFire®
ERK1/2 phosphorylation kit in hCB1R CHO cells. d ABM300 has no effect alone, but decreases the Emax for CP55,940-stimulated ERK
phosphorylation in a concentration-dependent manner in hCB1R CHO cells. e ABM300 decreases the Emax of AEA-stimulated ERK1/2
phosphorylation in a concentration-dependent manner in hCB1R CHO cells. f ABM300 concentration-dependently inhibits CP55,940-(EC80 of
40 nM) mediated inhibition of forskolin-stimulated cAMP signaling in hCB1R CHO cells. Data shown as mean ± SEM from 3–5 independent
experiments conducted in triplicate. g BRET CAMYEL real-time cAMP signaling data in hCB1R HEK cells, showing ABM300 concentration-
dependently inhibiting the reduction in cAMP level induced by 5 µM forskolin and 1 µM CP55,940; the time-dependent activity of ABM300 is
particularly apparent at moderate concentrations (1 µM and 100 nM), in which the onset of the ABM300 effect is delayed (representative
experiment). h Area-under-the-curve analysis of g, showing that ABM300 concentration-dependently inhibits CP55,940-mediated cAMP
reductions in HEK cells. At high concentrations of ABM300, cAMP levels are increased above forskolin alone (100%).
Fig. 3 ABM300 (10mg/kg) has no effect in the cannabinoid-induced tetrad, when compared to THC (10mg/kg). Cannabinoid-induced
tetrad measuring a percent inhibition of locomotor activity (15 min), b rectal temperature (°C), c catalepsy-induced immobility time (s), and
d tail withdrawal (% MPE). ABM300 (10 mg/kg) alone has no effect on all outputs, when compared to vehicle and THC. All tests performed in
male mice, ABM300 or THC were administered 30min prior to behavioral testing via i.p. injection. Data shown as mean ± SEM, *p ≤ 0.05
compared to vehicle, ****p < 0.0001, one-way ANOVA, multiple comparisons, post-hoc Sidak’s test. Effect of treatment a F[2,27]= 37.47, p <
0.0001, b F[2,27]= 85.58, p < 0.0001, c F[2,27]= 13.72, p < 0.0001, and d F[2,26]= 46.67, p < 0.0001.
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whereas rimonabant significantly reduced open arm time com-
pared to vehicle (p= 0.0059).
ABM300 decreases novelty-induced hyperactivity, exaggerated
stereotypy, and vertical exploration in GluN1KD mice
GluN1KD mice display hyperactivity, increased stereotypy and
vertical exploration patterns, along with impairment in sensorimotor
gating [26–29]. GluN1KD mice do not display a difference in Cnr1
mRNA expression in key brain regions mediating these behaviors
(Supplementary Fig. S4). ABM300 decreased the number of
dysregulated behaviors in the GluN1KD model of hyperdopaminer-
gia (Fig. 4). Hyperactivity (Fig. 4a, b) was affected by genotype (F
[1,94]= 100.7, p < 0.0001), and GluN1KD mice responded to
ABM300 (p < 0.0001) when compared to vehicle. Significant effects
of genotype were observed for stereotypy and vertical exploration
(Fig. 4c, d) (F[1,94]= 223.6, p < 0.0001; F[1,94]= 70.87, p < 0.0001,
respectively). ABM300 significantly reduced exaggerated stereotypic
activity (Fig. 4c), as well as phenotypic increased rearing behavior
(Fig. 4d) (p < 0.0001). Sensorimotor gating deficits, along with
acoustic startle response, did not respond to ABM300 or the
atypical antipsychotic olanzapine (4 dB: F[2,95]= 1.068, p= 0.3476;
8 dB: F[2,95]= 0.4576, p= 0.6342; 16 dB: F[2,95]= 0.4790, p= 0.6209;
ASR: F[2,95]= 3.016, p= 0.0537) (Supplementary Fig. S5).
ABM300 decreases novelty-induced hyperactivity, exaggerated
stereotypy, vertical exploration, and normalizes pre-pulse
inhibition (PPI) in DATKO mice
The DATKO mouse, another model of hyperdopaminergia, displays
hyperactivity, increased stereotypy and vertical exploration, with
an impairment in sensorimotor gating [24, 31]. Similar to the
GluN1KD model, DATKO mice showed no change in Cnr1 mRNA
expression (Supplementary Fig. S6). ABM300 normalized dysregu-
lated hyperactivity, stereotypic movements, vertical exploration
and sensorimotor gating in the DATKO mice (Fig. 5), a pattern of
findings similar to what was seen in the GluN1KD model (Fig. 4).
For the hyperactivity measure (Fig. 5a), a significant interaction was
found between ABM300 and genotype (F[1,46]= 9.38, p= 0.004),
indicating that ABM300 has genotype-specific effects on the
exacerbated hyperactivity endophenotype in DATKO. There was an
effect of genotype on exaggerated stereotypic movements and
mania-like rearing behavior (F[1,46]= 40.18, p < 0.001; F[1,46]=
26.50, p < 0.001, respectively), which ABM300 had a beneficial
effect in decreasing (F[1,46]= 14.22, p < 0.001; F[1,46]= 7.38, p=
0.009, respectively) (Fig. 5b, c). Furthermore, the actions of ABM300
extended to sensorimotor gating deficits present in DATKO
(Fig. 5d), with a rescue of the PPI deficit at the 16 dB pre-pulse
interval (p= 0.018). Neither genotype, nor treatment with ABM300,
Fig. 4 ABM300 corrects hyperactivity, aberrant stereotypic movements and rearing behavior, resulting from hyperdopaminergia in the
GluN1KD mouse model. ABM300 (ABM; 10mg/kg) decreases novelty-induced hyperactivity (time-course of distance traveled—a, total
distance traveled—b) aberrant stereotypic movements (c), and mania-like rearing behavior (d), in the open-field test. Effects of ABM300 are
similar to those seen with olanzapine (OLA—1mg/kg). All tests balanced for sex, drugs administered 30min before test via i.p. injection. Data
shown as mean ± SEM, *p ≤ 0.05 compared to vehicle (within genotype), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, two-way ANOVA,
multiple comparisons, post-hoc Sidak’s test. a, b Effect of genotype F[1,94]= 100.7, p < 0.0001, effect of drug F[2,94]= 11.23, p < 0.0001,
interaction of genotype x drug F[2,94]= 7.554, p= 0.0009. c Effect of genotype F[1,94]= 223.6, p < 0.0001, effect of drug F[2,94]= 12.13, p <
0.0001, interaction of genotype x drug F[2,94]= 4.206, p= 0.0178. d Effect of genotype F[1,94]= 70.87, p < 0.0001, effect of drug F[2,94]=
8.137, p= 0.0006, interaction of genotype x drug F[2,94]= 5.679, p= 0.0047.
A novel allosteric modulator of the cannabinoid. . .
CA Mielnik et al.
6
Neuropsychopharmacology (2020) 0:1 – 10
had an effect on the acoustic startle response in the DATKO model
(data not shown, genotype: p= 0.214, ABM300: p= 0.516).
ABM300 has no effect on the conditioned avoidance response
(CAR)
The CAR task has been used as a test to infer antipsychotic efficacy
via the selective suppression of the avoidance response [41, 42].
Administration of olanzapine (1mg/kg), but not ABM300 (10mg/kg),
attenuated avoidance behavior in CAR testing (Supplementary
Fig. S7). A main effect of drug was observed (p= 0.007).
Furthermore, olanzapine, but not ABM300, enhanced escape
responding during CAR (Supplementary Fig. S7B), with a main
effect of drug treatment (p= 0.011) and an interaction between
drug treatment and testing day (p= 0.034). Lastly, neither ABM300
nor olanzapine affected escape failures (Supplementary Fig. S7C).
ABM300 did not induce catalepsy, or changes in body temperature
(Supplementary Fig. S7D,E).
DISCUSSION
There is growing interest in the possible therapeutic potential of
CB1R allosteric molecules [21]. Here, we show for the first time that a
novel CB1R allosteric modulator ameliorates select disrupted
behaviors in two distinct models of hyperdopaminergia. The rescue
of these phenotypes by ABM300 occurred without adverse
anxiogenic-like or cannabimimetic effects traditionally observed with
orthosteric CB1R inverse agonists. Thus, these findings represent the
first study demonstrating the potential for the use of a CB1R allosteric
modulator as a therapeutic strategy for the treatment of hyperdo-
paminergic states, such as psychosis and mania.
Our molecular docking data indicate that ABM300 binds to the
recently elucidated binding site for the original allosteric
modulator Org275 [16]. The Org275-binding site on CB1R overlaps
with a cholesterol-binding site, which is an extrahelical site within
the inner leaflet of the membrane. The model is broadly in
agreement with literature demonstrating that Org275 apparently
stabilizes a high affinity, agonist bound CB1R [43], which may
impede activation of selected downstream signaling pathways.
The structure proposes a mechanism by which Org275, binding to
the cholesterol site, captures an intermediate conformation that
binds the orthosteric agonist and also inhibits G protein coupling.
The model accommodates the complex effects of Org275 on CB1
orthosteric ligand binding, including the increase in Bmax of
agonists. ABM300 displays a similar in vitro pharmacological
profile to Org275 [13, 15], whereby it increases CB1R agonist
binding with an α value > 1 (4.33 ± 0.79) [44], but acts as a
Fig. 5 The effectiveness of ABM300 is recapitulated in a second, distinct, mouse model of hyperdopaminergia, the DATKO model, with
additional restoration of sensorimotor deficits. ABM300 (10mg/kg) decreases novelty-induced hyperactivity (total distance traveled; cm) (a),
aberrant stereotypic movements (b), and mania-like vertical exploration (c) in the open-field test. ABM300 ameliorates sensorimotor gating
deficits (d), rescuing the PPI deficit at 16 dB pre-pulse. All tests balanced for sex, drugs administered 30min before test via i.p. Data shown as
mean ± SEM, *p ≤ 0.05 compared to vehicle (within genotype), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, two-way ANOVA, multiple
comparisons, post-hoc Sidak’s test. a Effect of genotype F[1,43]= 116.9, p < 0.0001, effect of drug F[1,43]= 13.89, p= 0.0006, interaction of
genotype x drug F[1,43]= 9.384, p= 0.0038. b Effect of genotype F[1,43]= 40.18, p < 0.0001 and effect of drug F[1,43]= 14.22, p= 0.0005,
c Effect of genotype F[1,42]= 36.03, p < 0.0001, effect of drug F[1,42]= 19.16, p < 0.0001, interaction of genotype x drug F[1,42]= 10.80, p=
0.0021, d (4 dB) effect of genotype F[1,43]= 8.509, p= 0.0056, (8 dB) effect of genotype F[1,43]= 7.303, p= 0.0098, (16 dB) effect of genotype
F[1,43]= 4.713, p= 0.0355.
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functional inhibitor of CB1R agonist-mediated β-arrestin recruit-
ment (IC50, 50 nM), ERK phosphorylation (IC50, 47 nM), and cAMP
inhibition (IC50, 380 nM).
As previously described [38], the unique time-dependent
mechanism of action of ABM300 (Fig. 2g) posits that at moderate
concentrations (high nM/low µM), early agonist signaling may
remain unaffected; with inhibition initiating after a lag. These
observations indicate that the molecular mechanism of action of
ABM300 is related to previously characterized CB1R allosteric
modulators such as Org275 and PSNCBAM-1 [38]. This may
introduce potential for a unique kinetic profile of modulation of
endocannabinoid signaling. The consequences of such effects at a
network level and in a disease state are highly complex but may
underlie the beneficial effects observed with ABM300 in the
genetic models of hyperdopaminergia. Furthermore, expression
levels, affinity, and pre-coupling of CB1Rs can significantly differ in
various neuronal cell types; CB1R on GABAergic interneurons have
significantly higher agonist affinity than those found on glutama-
tergic terminals, but the coupling efficacy of glutamatergic CB1R is
significantly higher [45, 46]. This expression and affinity profile
leads to the complex nature in the function of the endocannabi-
noid system, which explains the diverse effects of certain
cannabinoid drugs, and the opposing effects in different illnesses
[46]. We hypothesize that, in the genetic murine models of
hyperdopaminergia, ABM300 acts as a modulator of endogenous
CB1R signaling in vivo and, potentially, selectively modulates the
endocannabinoid system in specific neurotransmitter system
pathways to ameliorate the dysregulated behaviors observed in
these mice.
Studies have demonstrated that administration of compounds
that increase endocannabinoid levels modulate a number of
schizophrenia-like responses in mice [47]. Studies in cultured cells
have shown that the related compound, Org275, causes migration
of CB1R to the soma, while cholesterol, which binds to the same
site as ABM300 and acts as a positive modulator, allows for the
enrichment of CB1R at the axon [48]. Thus, in addition to complex
effects on endocannabinoid affinity and signaling, there is the
potential for the modulation of topological CB1R membrane
localization by CB1R allosterics. The consequences of this in a
complex neuronal network, and pathological states, are yet to be
fully elucidated.
To assess psychosis-like behaviors, and therapeutic efficacy of
ABM300, we focused on two main behavioral categories:
exploratory behavior (hyperactivity) and sensorimotor gating
(disruption in PPI). The literature related to psychosis-like
behaviors in genetically modified mouse models has classically
focused on the same two categories [49]. Although these
behaviors do not directly translate to human symptoms present
in the disease, they do mimic the neurotransmitter changes that
are involved in psychotic symptoms. It has been accepted that
subcortical hyperdopaminergia is implicated in psychosis, con-
firmed further by the neuropharmacological action of antipsycho-
tic drugs currently available; all licensed pharmacological
treatments of psychosis (antipsychotics) require interactions with
the dopamine D2 receptor [50]. Therefore, by assessing locomotor
behavior within this study, we can infer that, driven by subcortical
dopamine levels, an increase in dopamine leads to enhanced
motor activity (either horizonal, rearing, and/or stereotypy) [49].
Meanwhile, disruption in PPI allows for a more straightforward
phenotypic analysis of psychosis, as it has been reported in a
number of psychiatric diseases, particularly schizophrenia and
psychosis [51].
Here, we show that ABM300 restores dysregulated dopamine-
mediated exploratory activity in both genetic models: decreasing
exaggerated hyperactivity, stereotypy and rearing. Furthermore,
ABM300 rescues PPI deficits in the DATKO model. Since psychosis
symptomology is never present alone in a disease state such as
schizophrenia, it would be intriguing to investigate the effects of
ABM300 in other symptomatic domains, such as cognition. CB1R
antagonism and loss of function may enhance some forms of
learning and memory, and it is possible that CB1R-negative
allosteric modulators may be pro-cognitive in preclinical schizo-
phrenic models [52, 53].
We saw no effect of the compound in CAR in rat even though
olanzapine produced significant suppression of CAR as has been
shown in previous studies [54]. CAR is an extensively validated
preclinical test used to predict therapeutic efficacy of antipsycho-
tics that directly target the dopaminergic and serotoninergic
receptor systems [42, 55]. This experiment further supports our
assertion that ABM300’s antipsychotic effects are not mediated via
dopamine D2 receptors, as considerable occupancy of striatal D2
receptors is required to see suppression of CAR (65–80% for
typical antipsychotics, ~ 50% for atypical antipsychotics like
clozapine) [42].
It is important to note that we do not have direct evidence for the
involvement of the CB1R in the in vivo effect of ABM300 in genetic
models. Directly implicating CB1R is challenging. One approach
would be to create a double knockout of CB1R-/- and DAT-/- or
GluN1-/-. However, given the crucial role of the CB1R in
dopaminergic and glutamatergic signaling, there is a strong
likelihood that the double knockouts could have a novel phenotype
(such as seizures) or that previous phenotypes would be
exacerbated [56, 57]. Furthermore, genetic manipulation of the
CB1R has been shown to have effects on dopamine signaling
[58, 59]. Another approach would be to investigate whether a CB1R
orthosteric antagonist would block the effects of ABM300, thereby
implicating CB1R. However, there is also doubt as to whether an
orthosteric CB1R antagonist would block the effects of a negative
allosteric inhibitor (antagonist blocking inhibitor); it is conceivable
that a synergistic effect might be observed. Taken together, these
limitations highlight the complexity of directly implicating CB1R in
the mechanism of action of ABM300 in vivo in these genetic models.
We plan to make this the subject of future investigations involving a
variety of in vivo and ex vivo approaches. The pharmacological
profiling and assessment of the potential for off-target interactions
of ABM300 in binding screens suggest that the compound is CB1R-
selective. Taken together, the potent inhibitory effect of the
compound on CB1R signaling at nM concentrations in vitro and
the favorable PK and brain penetration data, there is substantial
support for the hypothesis that the CB1R mediates the effects of
ABM300 in vivo in the genetic mouse models of hyperdopaminer-
gia. It is also notable that the present study only included acute
administration of one dose of ABM300. Future experiments will
focus on various dose regimens, chronic dosing, development of
tolerance and the effects of ABM300 in combination with an
antipsychotic.
The data presented here offer the first evidence that acute
administration of a CB1R allosteric modulator, with a unique
pharmacological profile, effectively ameliorates certain behavioral
deficits in two distinct models of increased dopamine. These data
highlight that the allosteric-binding pocket on the CB1R warrants
further investigation as a potentially important therapeutic target
in psychiatry.
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